# Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

> **NCT01203787** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 120 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib Standard Dosing Regimen
- **DRUG:** Sorafenib Ramp-Up Regimen

## Key facts

- **NCT ID:** NCT01203787
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-03
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203787, "Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01203787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*